Pre-made Inclacumab benchmark antibody ( Whole mAb, anti-SELP therapeutic antibody, Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Inclacumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inclacumab (LC1004-002) (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease.
| Products Name (INN Index) | Pre-Made Inclacumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody |
|---|---|
| INN Name | Inclacumab |
| Target | SELP |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Genmab,Roche,Global Blood Therapeutics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Acute coronary syndromes,Myocardial infarction,Peripheral vascular disorders |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | SELP |
| Package |
